American Journal of Epidemiology Vol. 127, No. 5: 990-998
Copyright © 1988 by The Johns Hopkins University School of Hygiene and Public Health
research-article |
MENOPAUSE AND OVARIAN CANCER
1Environmental Epidemiology Branch, National Cancer Institute Bethesda, MD
2Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, George Washington University Medical Center Washington, D.C.
3Armed Forces Institute of Pathology Washington, D.C.
Reprint requests to Dr. Patricia Hartge, NCI, Landow Building, Room 3C06, NIH, Bethesda, MD 20892
Using data from a study of 296 patients diagnosed in greater Washington, D. C., from 1978 to 1981 with primary epithelial ovarian cancer and 343 patients hospitalized for other conditions, the authors estimated the rate ratios according to various characteristics of the menopause. Menopause induced by hysterectomy with preservation of both ovaries was associated with a 30 per cent reduction in risk of later development of ovarian cancer. Age at natural menopause was not consistently related to risk. Women who used menopausal estrogens showed a 40 per cent decreased risk.
estrogens; hysterectomy; menopause; ovarian neoplasms
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
C. M. Greiser, E. M. Greiser, and M. Doren Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis Hum. Reprod. Update, September 1, 2007; 13(5): 453 - 463. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. V. Lacey Jr., L. A. Brinton, J. H. Lubin, M. E. Sherman, A. Schatzkin, and C. Schairer Endometrial Carcinoma Risks among Menopausal Estrogen plus Progestin and Unopposed Estrogen Users in a Cohort of Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1724 - 1731. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. V. Lacey Jr, P. J. Mink, J. H. Lubin, M. E. Sherman, R. Troisi, P. Hartge, A. Schatzkin, and C. Schairer Menopausal Hormone Replacement Therapy and Risk of Ovarian Cancer JAMA, July 17, 2002; 288(3): 334 - 341. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Riman, P. W. Dickman, S. Nilsson, N. Correia, H. Nordlinder, C. M. Magnusson, E. Weiderpass, and I. R. Persson Hormone Replacement Therapy and the Risk of Invasive Epithelial Ovarian Cancer in Swedish Women J Natl Cancer Inst, April 3, 2002; 94(7): 497 - 504. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Syed, G. Ulinski, S. C. Mok, G. K. Yiu, and S.-M. Ho Expression of Gonadotropin Receptor and Growth Responses to Key Reproductive Hormones in Normal and Malignant Human Ovarian Surface Epithelial Cells Cancer Res., September 1, 2001; 61(18): 6768 - 6776. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Rodriguez, A. V. Patel, E. E. Calle, E. J. Jacob, and M. J. Thun Estrogen Replacement Therapy and Ovarian Cancer Mortality in a Large Prospective Study of US Women JAMA, March 21, 2001; 285(11): 1460 - 1465. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. B. Ness and C. Cottreau Possible Role of Ovarian Epithelial Inflammation in Ovarian Cancer J Natl Cancer Inst, September 1, 1999; 91(17): 1459 - 1467. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Hankinson, D. J. Hunter, G. A. Colditz, W. C. Willett, M. J. Stampfer, B. Rosner, C. H. Hennekens, and F. E. Speizer Tubal Ligation, Hysterectomy, and Risk of Ovarian Cancer: A Prospective Study JAMA, December 15, 1993; 270(23): 2813 - 2818. [Abstract] [PDF] |
||||




